default author photo

Valter Torri

Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Department of Oncology

Milan

Italy

SCHOLARLY PAPERS

2

DOWNLOADS

182

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Impact of Platinum-Based Chemotherapy and CTLA-4 Inhibition on Acquired Resistance to First-Line Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer: A Systematic Review and Reconstructed Individual Patient Data Analysis

Number of pages: 24 Posted: 26 Apr 2025
Università Vita-Salute San Raffaele - San Raffaele Hospital, University of Naples Federico II, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, University of Verona, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, University of Naples Federico II, Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust, University of Turin - Department of Oncology, Harvard University - Dana-Farber Cancer Institute, Imperial College London, German Centre for Lung Research - Lungen Clinic Grosshansdorf, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Laboratory of Methodology of Systematic Reviews and Guidelines Production, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Department of Oncology, AORN dei Colli - Monaldi Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 98 (704,534)

Abstract:

Loading...

acquired resistance, platinum-based chemotherapy, CTLA-4 inhibitors, immunotherapy, non-small cell lung cancer

2.

A Systematic Review and Meta-Analysis on the Optimal Treatment Duration of CHEckpoint InhibitoRS in Solid Tumors: The OTHERS Study

Number of pages: 37 Posted: 08 Feb 2022
Sapienza University of Rome - Department of Maternal, Infantile, and Urological Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Laboratory of Methodology of Systematic Reviews and Guidelines Production, Grande Ospedale Metropolitano Niguarda - Department of Thoracic Oncology, University of Parma - Medical Oncology Unit, Università Vita-Salute San Raffaele - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Oncology, University of Parma - Medical Oncology Unit, Azienda Ospedaliero Universitaria di Modena - Department of Oncology, Azienda Ospedaliero-Universitaria Careggi, Università Vita-Salute San Raffaele - Department of Medical Oncology, University of Insubria, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS - Department of Oncology, Sapienza University of Rome - Department of Maternal, Infantile, and Urological Sciences and Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Oncology
Downloads 84 (777,583)

Abstract:

Loading...

Immunotherapy, duration, survival, solid tumors